US equities |
MU $1,073.11 ▼-1.37% NVDA $235.57 ▼-0.80% SNDK $1,645.60 ▼-2.77% PLTR $198.73 ▲+2.37% AMD $633.64 ▼-1.89% INTC $109.60 ▼-3.11% SPCX $163.62 ▼-2.37% META $719.08 ▼-0.31%
FinancialContent

Oncotelic Therapeutcs Inc (OP:OTLC)

0.0219 -0.0021 (-8.75%)
Delayed Quote Updated: 11:18 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncotelic Therapeutcs Inc

< Previous 1 2 3 4 5 6 7 Next >
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026
Via Investor Brand Network
Topics Artificial Intelligence Regulatory Compliance
News headline image
Growth Stocks: NGTF, AMLM, CSDX, OTLC, ECGI Across Robotics, Precious Metals, MedTech and Blockchain
Via AB Newswire
Topics Economy Intellectual Property
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends
Via Investor Brand Network
Topics Intellectual Property
News headline image
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
From NetworkNewsWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
From BioMedWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery
Via Investor Brand Network
Topics Intellectual Property
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus
Via Investor Brand Network
Topics Intellectual Property
Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline
Via Investor Brand Network
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform
Via Investor Brand Network
Topics Artificial Intelligence Regulatory Compliance
Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences
Via Investor Brand Network
Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) identifies Biomarker Signature Predicting Sensitivity to IV Sapu003
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% JV Reports IV Sapu003 Cuts GI Exposure to Everolimus by Up to 67-Fold
Via Investor Brand Network
Topics Intellectual Property
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) JV Sapu Nano Presents Data Showing Deciparticle Platform Supports Broad Hydrophobic Drug Formulation
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Rising Biotech Valuations
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
From BioMedWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >